On Wednesday, test results were released that researchers called "simply stunning": the drug Herceptin was shown to dramatically reduce the recurrence of a common type of breast cancer in its early stage after chemotherapy.
Three international clinical trials on more than 6,500 patients showed that the drug, which has been mostly used to prolong survival of patients with advanced HER2 breast cancer, is profoundly effective in treating those in the early stages as well.
A summary of the trials in the New England Journal of Medicine characterized the results as so positive that Herceptin could possibly lead to "a cure" for the disease.
"This is probably the biggest evidence of a treatment effect I've ever seen in oncology," said Richard Gelber of the Dana-Farber Cancer Institute, which took part in the tests. "It is quite remarkable," Gelber said.
"Clearly, the results ... are not evolutionary but revolutionary," doctor Gabriel Hortobagyi said in the journal.
The particularly aggressive protein HER2 is involved in up to 30 percent of the more than 1 million new breast cancer cases diagnosed worldwide each year. Approximately 400,000 people die annually from the disease.
Herceptin, a monoclonal antibody drug produced in the US by the firm Genentech and known by the generic name trastuzumab, has been used therapeutically on women in the advanced stages of HER2 breast cancer following chemotherapy since 1998.
Because HER2 is frequently resistant to chemotherapy, Herceptin is administered to block the activity of the protein to prevent the cancer's recurrence.
In the largest of the trials, in 2001 the Breast International Group together with European Herceptin manufacturer Roche began testing its effect on 5,000 women in 39 countries who were diagnosed with HER2 cancer in the early stages. Within one year Herceptin users showed clearly positive results.
The rate of recurrence was slashed by 46 percent. This meant that, two years after the beginning of the treatment, there was an 8 percent increase in the number of women who were disease-free.
"The results are simply stunning," Hortobagyi said. "All three trials show highly significant reductions in the risk of recurrence, of a magnitude seldom observed in oncology trials."
The tests also showed a low level of side effects on patients using Herceptin, the Dana-Farber institute reported.
Previous tests of Herceptin use following chemotherapy had generated a significant number of cardiac problems in patients.
Nearly half of China’s major cities are suffering “moderate to severe” levels of subsidence, putting millions of people at risk of flooding, especially as sea levels rise, according to a study of nationwide satellite data released yesterday. The authors of the paper, published by the journal Science, found that 45 percent of China’s urban land was sinking faster than 3mm per year, with 16 percent at more than 10mm per year, driven not only by declining water tables, but also the sheer weight of the built environment. With China’s urban population already in excess of 900 million people, “even a small portion
UNSETTLING IMAGES: The scene took place in front of TV crews covering the Trump trial, with a CNN anchor calling it an ‘emotional and unbelievably disturbing moment’ A man who doused himself in an accelerant and set himself on fire outside the courthouse where former US president Donald Trump is on trial has died, police said yesterday. The New York City Police Department (NYPD) said the man was declared dead by staff at an area hospital. The man was in Collect Pond Park at about 1:30pm on Friday when he took out pamphlets espousing conspiracy theories, tossed them around, then doused himself in an accelerant and set himself on fire, officials and witnesses said. A large number of police officers were nearby when it happened. Some officers and bystanders rushed
Beijing is continuing to commit genocide and crimes against humanity against Uyghurs and other Muslim minorities in its western Xinjiang province, U.S. Secretary of State Antony Blinken said in a report published on Monday, ahead of his planned visit to China this week. The State Department’s annual human rights report, which documents abuses recorded all over the world during the previous calendar year, repeated language from previous years on the treatment of Muslims in Xinjiang, but the publication raises the issue ahead of delicate talks, including on the war in Ukraine and global trade, between the top U.S. diplomat and Chinese
HYPOCRISY? The Chinese Ministry of Foreign Affairs yesterday asked whether Biden was talking about China or the US when he used the word ‘xenophobic’ US President Joe Biden on Wednesday called for a hike in steel tariffs on China, accusing Beijing of cheating as he spoke at a campaign event in Pennsylvania. Biden accused China of xenophobia, too, in a speech to union members in Pittsburgh. “They’re not competing, they’re cheating. They’re cheating and we’ve seen the damage here in America,” Biden said. Chinese steel companies “don’t need to worry about making a profit because the Chinese government is subsidizing them so heavily,” he said. Biden said he had called for the US Trade Representative to triple the tariff rates for Chinese steel and aluminum if Beijing was